In silico design of a multi-epitope vaccine against HPV16/18.

ABSTRACT:

Background

Cervical cancer is the fourth most common cancer affecting women and is caused by human Papillomavirus (HPV) infections that are sexually transmitted. There are currently commercially available prophylactic vaccines that have been shown to protect vaccinated individuals against HPV infections, however, these vaccines have no therapeutic effects for those who are previously infected with the virus. The current study's aim was to use immunoinformatics to develop a multi-epitope vaccine with therapeutic potential against cervical cancer.

Results

In this study, T-cell epitopes from E5 and E7 proteins of HPV16/18 were predicted. These epitopes were evaluated and chosen based on their antigenicity, allergenicity, toxicity, and induction of IFN-γ production (only in help

SUBMITTER: Sanami S 

PROVIDER: S-EPMC9344258 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature